TVTX Earnings & Financial Statements
Travere Therapeutics, Inc.
$53.27
+$1.47(+2.84%)
41
Overall
40
Value
18
Tech
65
Quality
Market Cap
$5.02B
Volume
2.06M
52W Range
$22.59 - $68.73
Target Price
$75.21
TVTX earnings and financial statements: Travere Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
TVTX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $490.73M | $233.18M | $145.24M | $109.46M | $131.84M |
| Cost of revenue | $10.34M | $7.74M | $11.45M | $4.42M | $3.82M |
| Operating income | -$62.82M | -$323.83M | -$388.14M | -$319.81M | -$161.76M |
| EBITDA | $23.86M | -$264.05M | -$324.53M | -$297.80M | -$184.46M |
| Net income | -$25.55M | -$321.55M | -$111.40M | -$278.48M | -$180.09M |
| EPS (diluted) | $-0.29 | $-4.08 | $-1.50 | $-4.37 | $-3.01 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $605.19M | $594.13M | $788.91M | $672.59M | $776.63M |
| Total liabilities | $490.36M | $535.05M | $588.10M | $629.73M | $474.52M |
| Shareholders’ equity | $114.83M | $59.08M | $200.81M | $42.85M | $302.11M |
| Cash and equivalents | $93.03M | $58.53M | $58.18M | $61.69M | $165.75M |
| Long-term debt | $322.86M | $327.50M | $399.88M | $403.06M | $258.08M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $37.78M | -$237.47M | -$280.02M | -$186.29M | -$14.79M |
| Capital expenditure | -$58.16M | -$36.21M | -$41.59M | -$28.37M | -$24.15M |
| Free cash flow | -$20.37M | -$273.69M | -$321.61M | -$214.66M | -$38.94M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TVTX | $53.27 | +2.8% | 2.06M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Travere Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW